TCRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

TC

Mkt Cap

$16.2M

Volume

560.22K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationTScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients assessed after a second infusion showing complete chimerism. The commercial-ready manufacturing process achieved a 90% success rate. The company remains on track to initiate its Phase 3 ALLOHA-2 study this month.GlobeNewswire Inc. · Jun 22, 2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateTScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026. Cash position of $128.1 million is expected to fund operations into H2 2027.GlobeNewswire Inc. · May 6, 2026

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceTScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for candidates TSC-102-A01 and TSC-102-A03.GlobeNewswire Inc. · Apr 8, 2026

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chimerism data in Q2 2026 and launch a pivotal trial for TSC-101, while initiating Phase 1 studies for both TSC-102 candidates in the second half of 2026.GlobeNewswire Inc. · Feb 26, 2026

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionTScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.GlobeNewswire Inc. · Dec 6, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsMultiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.Benzinga · Dec 4, 2025

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025TScan Therapeutics will present two abstracts at the ACR Convergence 2025, highlighting novel discoveries in T cell targets for autoimmune disorders like Ankylosing Spondylitis and Scleroderma using their TargetScan technology.GlobeNewswire Inc. · Sep 17, 2025

TScan Therapeutics to Participate in Upcoming Investor ConferencesTScan Therapeutics, a clinical-stage biotech company, announced participation in upcoming investor conferences and provided updates on its T cell receptor (TCR) therapies for cancer treatment, including ongoing clinical trials for hematologic malignancies and solid tumors.GlobeNewswire Inc. · Sep 3, 2025

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceTScan Therapeutics, a clinical-stage biotechnology company, announced updates from its PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials, and plans to file an IND application for TSC-102-A0301 (CD45; HLA-A*03:01) with the FDA.GlobeNewswire Inc. · May 28, 2025

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer BiotechsThe article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.Benzinga · May 23, 2025

TC

TCRXTScan Therapeutics, Inc. Common Stock

TCRX

Pay with—

Available Balance0.00

Your PositionYou don't own any TCRX yet.

Related Tickers

Earnings